Results 1 to 10 of about 272,392 (299)
Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells. [PDF]
Int J Mol Sci, 2019 Programmed cell death-1 (PD-1) is a cell surface receptor that dampens adaptive immune responses. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. This results in the inhibition of T cell proliferation, differentiation, cytokine secretion, and cytolytic function.
Mallett G, Laurence A, Amarnath S.
europepmc +6 more sources
Structure and interactions of the human programmed cell death 1 receptor. [PDF]
J Biol Chem, 2013 PD-1, a receptor expressed by T cells, B cells, and monocytes, is a potent regulator of immune responses and a promising therapeutic target. The structure and interactions of human PD-1 are, however, incompletely characterized. We present the solution nuclear magnetic resonance (NMR)-based structure of the human PD-1 extracellular region and detailed ...
Cheng X +18 more
europepmc +5 more sources
bioRxiv, 2022 Innate Lymphoid Cells (ILCs) play a key role in tissue mediated immunity and can be controlled by co-receptor signaling. Here we define a subset of ILCs that are Tbet+NK1.1− and are present within the tumor microenvironment (TME).
Lim JX +16 more
europepmc +2 more sources
Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma. [PDF]
Cureus, 2017 Learning objectives To evaluate radiation-induced changes in patients with brain metastasis secondary to malignant melanoma who received treatment with Gamma Knife radiosurgery (GKRS) and programmed cell death 1 (PD-1) receptor antagonists.
Nordmann N +5 more
europepmc +2 more sources
In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network [PDF]
Journal of Biological Chemistry, 2017 Programmed cell death-1 (PD-1) is an inhibitory receptor with an essential role in maintaining peripheral tolerance and is among the most promising immunotherapeutic targets for treating cancer, autoimmunity, and infectious diseases. A complete understanding of the consequences of PD-1 engagement by its ligands, PD-L1 and PD-L2, and of PD-L1 binding to
Li, Kaitao +4 more
openaire +4 more sources
An update on immunotherapy with PD-1 and PD-L1 blockade [PDF]
Yeungnam University Journal of Medicine, 2021 Cancer is the leading cause of death and is on the rise worldwide. Until 2010, the development of targeted treatment was mainly focused on the growth mechanisms of cancer.
Sung Ae Koh
doaj +1 more source
Brain Sciences, 2022 Purpose: This study aims to investigate PD-1/PD-L1 expression patterns in paired primary and recurrent gliomas. Methods: From January 2008 to December 2014, 42 patients who underwent surgical resections of primary and recurrent gliomas were ...
Wei Yu +5 more
doaj +1 more source
Frontiers in Oncology, 2021 BackgroundProgrammed death 1/ligand 1 (PD-1/L1) inhibitors have acceptable antitumor activity in patients with platinum-resistant urothelial cancer (UC).
Zaishang Li +20 more
doaj +1 more source
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
BMC Cancer, 2022 Background Mantle cell lymphoma (MCL) has remained incurable in most patients. The expression of PD-L1 as a prognostic and predictive marker has not been fully evaluated in MCL.
Fereshteh Ameli +3 more
doaj +1 more source
Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression
Tzu Chi Medical Journal, 2022 Melanocytic nevi, dysplastic nevi, and melanoma are all derived from the pigment-producing cells, namely melanocytes. Concerning the clinical spectrum, cutaneous melanoma is the most aggressive skin cancer with a low survival rate, while nevi are the ...
Wei-Wen Sung, Chung-Hsing Chang
doaj +1 more source